Aspiration Thrombectomy An Easily Forgiven “Latecomer” by De Rosa, Salvatore et al.
Correspondence JACC Vol. 63, No. 19, 2014
May 20, 2014:2050–5
2052Letters to the EditorAspiration ThrombectomyFigure 1
Inﬂuence of Reperfusion Time in
Acute Coronary Revascularization
(A) Meta-regression analysis of all available studies comparing aspiration throm-
bectomy (AT) with standard percutaneous coronary intervention (PCI) (calculated
with the unrestricted maximum likelihood model), showing a signiﬁcant interaction
with the time to treatment, indicating that the reduction in mortality from AT versus
standard PCI is larger for longer ischemic times. Each study is represented by a
circle that shows the effect size. The area of each circle is proportional to the
weight of that study in the analysis. (B) Meta-regression analysis of all available
studies comparing AT with standard PCI (calculated with the unrestricted maximum
likelihood model), showing the interaction with the time to treatment, indicating
that the reduction in the rate of major adverse cardiovascular events (MACE)
versus standard PCI is larger for longer ischemic times. Each study is represented
by a circle that shows the effect size. The area of each circle is proportional to the
weight of that study in the analysis. (C) Rates of myocardial reperfusion in the
standard PCI (SP) and thrombus aspiration (TA) groups according to time to
treatment, from the study by De Vita et al. (4), and in the group of patients
receiving an embolic protection stent (EPS) from the study by Dudek et al. (5).
Whereas the efﬁcacy of PCI rapidly decreases with time, prevention of distal
embolization by either AT or EPS preserves the efﬁcacy of PCI on reperfusion rate
over longer times.An Easily Forgiven “Latecomer”
We read with interest the recently published meta-analysis on the
role of aspiration thrombectomy (AT) during primary percutaneous
coronary intervention (PCI) in acute myocardial infarction (AMI)
(1), in which the authors reported a signiﬁcantly better Throm-
bolysis In Myocardial Infarction (TIMI) blush grade and
ST-segment resolution in the manual AT group compared with the
PCI group. Consistently, they also reported a lower incidence of
major adverse cardiovascular events and lower mortality in the AT
group.
We agree with the editorial comment (2) that, although inter-
esting, these results are not conclusive. In fact, the relatively smaller
infarct size and near-normal left ventricular ejection fractions
reported in the single studies did not allow the demonstration of
conclusive clinical superiority of AT over PCI alone. This is a
rather common issue affecting clinical research in the ﬁeld of AMI.
In fact, disappointing results can be sometimes explained through
the so-called “quantitative interaction,” the principle that the
beneﬁt of a given treatment is larger in high-risk patients (3). We
also recognize the prognostic importance of ischemic time, which
Balan and Anderson elegantly underlined in Figure 1 in their
editorial comment, reporting infarct size as a function of ischemic
time (2). Consequently, AT should be performed when possible
and as fast as possible, like all treatments of AMI.
On the other hand, there is a further interesting aspect of manual
AT that is worth reporting but that the authors missed: the
beneﬁcial effect of AT over PCI alone is higher for longer ischemic
times, as shown by the meta-regression analysis we performed on
the same studies analyzed by Kumbhani et al. (1), and this effect is
evident for both mortality (Fig. 1A) and the rate of major adverse
cardiovascular events (Fig. 1B). This phenomenon can easily be
explained because we know that the efﬁcacy of PCI rapidly de-
creases over time, as for all treatments of AMI, whereas AT
seemingly holds its efﬁcacy over time. Our ﬁnding is in line with a
previous report by De Vita et al. (4) (Fig. 1C), showing that
increasing time to treatment was associated with a signiﬁcantly
decreased reperfusion rate in patients treated with PCI alone, but
no such trend was observed in patients treated with AT and PCI.
Although no mechanism has been identiﬁed for this phenomenon,
it is tempting to speculate that distal embolization may became
more relevant in later stages when the thrombus is increasingly
organized and more apt to disrupt in insoluble fragments. Inter-
estingly, the MASTER (MGUARD for Acute ST Elevation
Reperfusion) trial showed that the use of a mashed stent, designed
to trap and exclude a thrombus, helped maintaining the efﬁcacy of
PCI over time in patients with ST-segment elevation myocardial
infarction (Fig. 1C) (5).
These ﬁndings should not be misinterpreted, and the golden
AMI rule “earlier is better” holds true for AT and all other treat-
ments of AMI; however, these results suggest that AT could be of
precious help in those patients with AMI who present several hours
after symptom onset.
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An Easily Forgiven “Latecomer”We are thankful to De Rosa and colleagues for their additional
analysis of, and insight into the topic covered in our report (1).
Although we were unable to directly replicate their ﬁndings, their
ﬁndings are interesting and hypothesis generating. It is conceivable
that aspiration thrombectomy will have a U-shaped relationship with
ischemic time when more trials are included. With longer ischemic
times, the thrombus becomes more organized and is subsequently
harder to retrieve with manual aspiration catheters. This hypothesis
should be actively investigated in future studies on this topic.*Dharam J. Kumbhani, MD, SM
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in Diabetes Mellitus
No Magic Remedies
Cardiovascular (CV) prevention has long been a target of clinical trials
in diabetes mellitus (DM). Several of those trials, however, have been
unsuccessful. In an effort to address this issue, the recently published
PONTIAC(NT-proBNPGuidedPrimaryPrevention ofCVEvents
in Diabetic Patients) trial used natriuretic peptides (NPs) to select
patients who had a relatively greater need for CV prevention and
hence were probably more prone to improvement (1). This study was
successful, but there were some questions that arise from this and
previous trials on CV prevention in DM.
First, was the poor patient selection the main reason why the
previous trials failed? The interventions used by some of the pre-
vious trials also may have not been successful. For example, in the
ROADMAP (Randomized Olmesartan and Diabetes Micro-
albuminuria Prevention) trial, a high dose of an effective angiotensin
receptor inhibitor (20 mg olmesartan) was used to prevent micro-
albuminuria in patients with DM who did not have hypertension,
which resulted in high rates of hypotension and other complications
and thus treatment failure (2,3). In the PONTIAC trial, a small but
signiﬁcant decline in estimated glomerular ﬁltration rate observed in
the intensiﬁed treatment group may be of some concern.
Second, what is the underlying pathophysiology for a mild in-
crease in NP levels in symptomatic patients with DM but without
known cardiac disease? There are several reasons for false-positive
or negative NP results, particularly in a population such as those
with DM, characterized by increased rates of comorbidities such as
renal dysfunction or obesity. In other words, what is the patho-
genetic process that we treat in those patients, and is the neuro-
hormonal blockage a suitable treatment for this process? In the
PONTIAC trial, there was no signiﬁcant reduction in NP levels in
the intensiﬁed treatment group during the study period, and thus
the reason for elevated levels of NP at baseline was probably not
addressed by the applied intervention.
Third, how should we titrate and monitor neurohormonal
blockade therapy in patients without a clear evidence-based indica-
tion for such a therapy, such as arterial hypertension or heart failure?
In the PONTIAC trial, treatment titration could not have been
guided or followed by NPs, because there was no signiﬁcant differ-
ence in NP levels between the 2 study groups at the end of the study.
Finally, could the positive results of the PONTIAC trial be
explained solely by the increased use of health care resources in
the intensiﬁed treatment group? Those patients were seen regu-
larly not only by diabetologists but also by cardiologists in the
cardiac outpatient clinics where they were receiving individu-
alized treatment, and that may be a sufﬁcient reason for a better
outcome. In other words, the success of the PONTIAC trial may
not lie on the use of NPs for patient selection but instead on the
